BG Medicine +24%, says clinical study shows performance of automated VIDAS

BG Medicine (BGMD +24.3%) shoots higher after announcing results of a clinical research study which validate the analytical and clinical performance of the automated VIDAS Galectin-3 assay that was developed by BHMD partner bioMérieux SA.

BGMD says measurement values obtained with the VIDAS Galectin-3 assay were found to be in excellent agreement with those obtained with the BGM Galectin-3 Test.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs